| CAS NO: | 211364-06-6 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 211364-06-6 |
| Canonical SMILES | O=C(N/C(C(N1CCCCC1)=O)=C(Br)\C2=CC=CC=C2OC)C3=CC=C([N+]([O-])=O)C=C3 |
| 分子式 | C22H22BrN3O5 |
| 分子量 | 488.33 |
| 溶解度 | DMSO : 25 mg/mL (51.19 mM) |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an IC50 of 0.13 uM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells[1][2][3]. AT-130 inhibits Wt HBV (IC50=2.4 µM), rtL180M HBV (IC50=9.8 µM), rtM204I HBV (IC50=35.6 µM)[1]. AT-130 (0.1, 1, 5, 10, 100 uM; for 7 days) causes dose-dependent inhibition of wt HBV replication in HepG2 cells transduced with HBV baculovirus. AT-130 at a concentration of 2.5 uM, reduces encapsidated HBV DNA by 50% (IC50) and at 18.5 uM by 90% (IC90)[1]. AT-130 has no toxic to either HepG2 or Huh-7 cells at concentrations of up to 250 µM[1]. AT-130 (0.005, 0.05, 0.5, 5, 50 uM) does not inhibit HBV DNA synthesis by blocking the HBV endogenous DNA polymerase reaction directly in Huh 7 or HepG2 cells. AT-130 inhibits HBV DNA replication in hepatoma cells but has no effect on viral DNA polymerase activity or core protein translation[3]. AT-130 (2.5, 18.5 uM) has no effect on total HBV RNA production but does reduce encapsidated RNA. AT-130 does not affect core protein or nucleocapsid production and the activity of the protein expression vector[3]. References: |
m.cnreagent.com